Competition Law in the Pharmaceutical Sector
The 1-day essential review of the latest market trends, policy and case law developments - including invaluable practical strategies to address the new challenges currently affecting the pharmaceutical sector across Europe
Featuring the European Commission, national regulators, in-house counsel and eminent lawyers from across the industry
EXPERT SPEAKER LINE-UP that was hand-selected to keep you up to date on the legal and regulatory developments affecting the pharma sector in 2018 included
Director Basic Industries, Manufacturing and Agriculture, DG Competition
highly focused sessions in 2018 included:
Hear from the Commission
Hear directly from Paul Csiszár, Director “Basic Industries, Manufacturing and Agriculture”, DG Competition, European Commission on how they are approaching the pharmaceutical sector. You will have an opportunity to pose your questions to Paul during the session.
Excessive Pricing Cases
Review the Commission’s forthcoming decisions and UK appeal in excessive pricing cases. Join us to analyse how the different national competition authorities are approaching these cases and gain practical strategies to reduce your competition law risk.
Rebates and Discounts
This session will offer a review of recent decisions and an in-depth analysis of why discounts and rebates are problematic. Our speakers will also offer practical strategies to help you reduce risks.
Reverse Patent Settlements
Gain a practical update on Lundbeck, Servier and UK Paroxetine cases. During this session you will have an opportunity to look over the pond and analyse what lessons can be learnt from US cases including the Actavis judgement.
During this interactive panel session our speakers from across Europe will review current developments at national levels. Key jurisdictions represented will include UK, France, Denmark, Italy and the Netherlands.
Biologics & Biosimilars
During this brand new session, our speakers will discuss what biologics and biosimilars are and what regulatory considerations they pose. We will analyse how the market should be defined, implications for mergers and remedies and what they mean for lifecycle management.